The company focuses on developing immune modulator product candidates for the treatment of COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. Its lead product candidate, CPI-006, is a potent humanized monoclonal antibody designed to react with a specific site on CD73. Corvus Pharmaceuticals also has other product candidates in its pipeline, including CPI-818, CPI-935, CPI-182, and Ciforadenant. With a team of accomplished scientists and top-tier investors, the company is well-positioned in the field of immuno-oncology, aiming to develop novel agents that target the immune system to treat patients with cancer.